Rosella Mechelli

TL;DR: The therapeutic implications of IP changes, considering the impact of MS-modifying therapies on gut barrier, as well as potential approaches to enhance or protect IP homeostasis are discussed.

TL;DR: In this article, the authors look over 18 months of the SARS-CoV-2 pandemic from the perspective of MS, dissect neuroinflammatory and demyelinating mechanisms associated with COVID-19, summarize pathophysiological crossroads between MS and SARS CoV2 infection, and discuss present evidence on COVID19 and its vaccination in people with MS.

TL;DR: In this article, the authors investigated telomere length and DNA double-strand breaks (histone variant pγ-H2AX) as predictive disease biomarkers in peripheral blood mononuclear cells (PBMC) from 25 premanifest subjects, 58 HD patients with similar CAG expansion in the huntingtin gene (HTT), and 44 healthy controls (HC).

TL;DR: A significant enrichment of SARS-CoV-2 interactors in immunological pathways and a strong association with autoimmunity and three prognostically relevant conditions that present more independent physiopathological subnetworks are found.

TL;DR: This work reviewed studies dealing with single genes of interest, and surveyed studies on the bioinformatic reworking of genome-wide association studies (GWAS) data, with aggregate analyses of many GWAS loci, each contributing with a small effect to the overall disease predisposition.